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1. Introduction
The surgical approach to cutaneous melanoma patients with clinically uninvolved regional
lymph nodes has been controversial. Although most patients with melanoma have no clini‐
cally palpable nodal disease at the time of presentation, some patients whose primary tumor
increases in thickness, has ulceration, and shows a high mitotic rate histologically harbor
clinically undetectable regional lymph node metastasis[1].
While some authors have advocated wide excision of the primary tumor with elective
lymph node dissection (ELND), others had recommended excision of the primary site alone
and therapeutic lymph node dissection (TLND) only when clinical nodal disease is present.
ELND is based on the concept that metastasis arises by passage of the tumor from the pri‐
mary to the regional lymph nodes and distant sites, in which case early LND will prevent
this metastatic progression. In contrast, TLND, which is a "watch and wait" approach, sug‐
gests that regional lymph node metastases are markers for disease progression and that
hematogenous distant metastases could occur without lymph node metastasis. Four
randomized prospective studies comparing ELND with TLND were reported[2-5]. The earli‐
er 2 studies conducted in the 1970s demonstrated no overall survival advantage for ELND[2,
3]. Accordingly, ELND was once contested and largely abandoned. Thereafter, the latter 2
studies conducted in the 1990s suggested the tendency, albeit statistically insignificant, that
patients with early regional metastases may benefit from ELND[4, 5]. However, in most
melanoma patients with no clinical nodal disease, microscopic nodal disease is absent at
presentation. These patients cannot benefit from ELND; if ELND were to be performed, they
would suffer from the cost, time, and morbidity of an unnecessary operation.
With respect to this controversy surrounding ELND, the technique of lymphatic mapping
and sentinel lymph node biopsy (SLNB) was introduced as a minimally invasive method for
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detection of microscopic regional lymph node metastases in the early 1990s[6]. Lymphatic
mapping is based on the concept that the lymphatic drainage from the skin to the regional
lymph node basins runs in an orderly, stepwise fashion. These lymphatic drainage patterns
would be the same as the dissemination of melanoma through the lymphatic system and
therefore predict the routes of metastatic spread of melanoma cells to the regional lymph
nodes (Fig. 1). Morton et al. first reported the details of the SLN technique using intradermal
blue dye injection around the primary site and reported that the SLN identification rate was
82% among 237 patients[6], which was considered a high identification rate at that time. In
the early 1990s, several authors evaluated this concept by performing synchronous ELND at
the time of SLNB[7-9]. A “false-negative” SLN was defined as microscopic metastasis in a
non-SLN despite the SLN showing no metastasis. These studies indicated that 5.8% of pa‐
tients had a false-negative SLN. In addition, Gershenwald et al. reported that only 4.1%
(10/243) of patients with a histologically negative SLN developed a nodal recurrence in the
previously mapped basin during a follow-up period of over 3 years[10]. This low false-nega‐
tive rate supported the SLN concept described above.
Figure 1. Lymphatic drainage from a primary tumor to sentinel lymph nodes. A sentinel node is sometimes locat‐
ed between the primary tumor and the regional nodal basins, in which case it is called an interval (unusual, in-transit,
ectopic) node. If the SLN has microscopic nodal metastasis, some of the second-tier nodes may also have metastasis.
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2. Technical advances in SLNB
Although the initial SLN identification rate using blue dye injections alone was approxi‐
mately 82%[6], the advent of lymphoscintigraphy and the intraoperative hand-held gamma
probe drastically improved the SLN identification rate. Studies comparing blue dye injection
alone with combined techniques using blue dye, lymphoscintigraphy, and an intraoperative
hand-held gamma probe showed a significant increase in SLN identification of up to 99%
with the combined techniques[11, 12], which has come to be recognized as the standard
technique of SLNB (Fig. 2). This combined technique also enables the surgeon to identify the
interval (unusual, in-transit, ectopic) nodes located outside the named regional nodal basins
(Fig. 3)[13-17]. The rate of interval SLN identification is reported to be approximately 5% to
10%, and the rate of microscopic metastasis in the interval nodes is approximately the same
as that in the SLN in the regional nodal basins[14].
However, SLNB in the head and neck has particular problems because the lymphatic drain‐
age in the head and neck is much more complex than those in the axillary and inguinal re‐
gions. Furthermore, the cervical and parotid lymph nodes are smaller and located in sites
that are not easily accessible, for example in the parotid gland, through which the facial
nerve passes [18, 19]. In addition, it is sometimes difficult to detect the lymphatic drainage
and SLN with lymphoscintigraphy because the SLN is often close to the highly radioactive
site where the tracer was injected, the so-called shine-through phenomenon[18, 19]. In addi‐
tion, in some cases the naked eye cannot confirm that an SLN has been dyed blue even after
injection of the blue dye because of the short staining period for blue dye in cervical SLNs
resulting from the rapid and complex cervical lymphatic flow[19]. In our experience too,
over half of the SLNs did not show any blue staining. Furthermore, some authors reported a
high false-negative rate of up to 44%, which leads to increased morbidity[20-22]. This high
rate may be caused by partially obstructed lymphatic vessels that do not allow for smooth
flow of nanocolloids with a size of 6 to 12 nm[23]. Although several authors have reported a
high identification rate in SLNB for head and neck melanoma[24-26], the identification rate
of SLNs for the standard technique in the cervical region is generally less than that in the
inguinal or axillary regions. In the MSLT-I trial reported by Morton et al., the SLN identifica‐
tion rate in the cervical region (84.5%) was clearly lower than that in the inguinal (99.3%) or
axillary regions (96.6%)[18].
Several studies on the SLNB technique using indocyanine green (ICG) injection in skin can‐
cer patients have demonstrated high SLN detection and identification rates, although these
studies involved mainly axillary and inguinal SLNBs and only a small number of cervical
SLNBs[23, 27-29]. ICG is a diagnostic reagent used in various examinations such as exami‐
nation for cardiac output or hepatic function and retinal angiography. It has a size of only
2.1 nm, binds with albumin, and generates a peak wavelength of 840 nm near-infrared fluo‐
rescence when excited with 765-nm light[30]. Using a near-infrared camera intraoperatively,
it is possible to observe the ICG as a subcutaneous lymphatic flow as well as SLNs in the
fluorescence images after intradermal injection of ICG around the primary tumor. (Fig. 4) In
our experience, the mean and median numbers of SLNs per basin were higher in the ICG
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group than in the standard-technique group. The small size of ICG allows a smooth flow
along the lymphatic vessels. It may lead to detection of SLNs not detectable by lymphoscin‐
tigraphy (Fig. 4C, D) owing to poor flow of the radioactive tracer and may reduce the false-
negative rate. Indeed, Stoffels et al. reported that 2 of 11 additional SLNs that were only
identified by the ICG technique showed microscopic metastasis[23].
In addition, the recently introduced hybrid single-photon emission computed tomography
with computed tomography (SPECT/CT) can visualize the exact anatomic location of the
SLN and second-tier nodes, which would be of great help in identifying the SLN, especially
those in the head and neck region[31, 32], as well as the interval nodes.
Figure 2. The technique of lymphatic mapping and sentinel lymph node biopsy (SLNB). (A) Primary melanoma
on the left chest. (B) Lymphoscintigraphy shows accumulation of 99Tc-tin colloid which was intradermally injected
around the primary tumor in the left axilla (arrow). (C) Intradermal injection of 2% isosulfan blue injection around the
primary site. (D) The exploration of the location of SLN using a hand-held gamma-probe and identification of a blue-
stained SLN. (E) Histopathologic detection of microscopic nodal metastasis.
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Figure 3. Detection of interval SLN. (A) Primary melanoma on the right heel. (B) Lymphoscintigraphy revealed accu‐
mulation in the right popliteal fossa. (C) Radioactive and blue-stained popliteal node, which had microscopic metasta‐
sis. (D) Popliteal lymph node dissection was performed.
Figure 4. SLNB using ICG. (A) SLNB for melanoma of the nose. The X mark on the left mandible indicates accumulation of
radioisotope (arrow). (B) A fluorescent submandibular SLN is visible through the incision using the near-infrared camera
(arrow). (C) SLNB for melanoma of the left temporal region. The X marks indicate accumulation of radioisotope. (D) An ad‐
ditional fluorescent SLN (arrow), which was not detected by lymphoscintigraphy, is observed through the overlying skin.
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3. Does SLNB-guided early lymph node dissection improve survival rate?
Whether patients who undergo complete lymph node dissection (CLND) after confirmation
of a positive SLN have a better prognosis than patients who undergo TLND after occurrence
of clinical nodal disease is controversial. The results of retrospective studies that compared
survival after CLND for a positive SLN with survival after TLND for clinical nodal disease
remain controversial. Several retrospective studies, including a multicentric study and a
matched control study, demonstrated a significant survival benefit for patients who under‐
went CLND for a positive SLN[33, 34]. In addition, a survival benefit was also demonstrated
for patients whose primary tumor thickness was between 1 mm and 4 mm and who under‐
went CLND for a positive SLN[35]. In contrast, other retrospective studies demonstrated no
significant difference in overall survival between patients who underwent CLND for a posi‐
tive SLN and those who underwent TLND for clinical nodal disease[36, 37].
The third interim analysis of the Multicenter Selective Lymphadenectomy Trial 1 (MLST-1),
the only randomized control trial with available results, failed to demonstrate a 5-year sur‐
vival advantage for the SLNB group when compared with the observation group and only a
disease-free survival benefit for the SLNB group[38]. In a subgroup analysis, patients who
underwent CLND for a positive SLN showed an improvement in 5-year survival of about
20% when compared with patients who underwent TLND after nodal observation and sub‐
sequently occurring clinical nodal disease (72.3% vs 52.4%; P=.004). The nodal recurrence
was lower in patients who had a negative SLN (4.0%) than in those who had a positive SLN
but were observed without early CLND (15.6%). From these results, the authors concluded
that microscopic metastasis would develop within the lymph nodes and that early LND
may lead to accurate staging and survival improvement.
However, whether SLNB and/or CLND would be a therapeutic procedure remains unclear,
and several authors have questioned this conclusion from the results of the MLST-1. First,
they claim that it was inappropriate to conclude that early CLND would improve survival
because this result was based on a postrandomization subgroup analysis[39]. Second, they
question whether all microscopic metastases will develop into clinical nodal disease. That is,
some microscopic metastases may show indolent behavior and not develop into clinical no‐
dal disease for a long time. In that case, comparison of the nodal recurrence rate between the
2 arms described above is an inappropriate analysis[37]. As a result, all that is currently
clear is that SLNB can provide staging information that predicts prognosis and may impact
clinical management.
4. Complete lymph node dissection
4.1. The role of complete lymph node dissection
The therapeutic value of CLND and appropriate selection of patients for CLND remain
questionable. The role of CLND in patients with positive SLNs is also a clinically important
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question because only 10% to 25% of patients with positive SLNs will have additional micro‐
scopic metastasis in non-SLNs[40-42], which means that approximately 80% of patients with
positive SLNs may be spared CLND. Several authors categorized the SLN as several varia‐
bles and tried to find a reliable indicator of non-SLN status[43, 44]. However, it remains un‐
clear what size of microscopic metastasis of the SLN or which histopathologic location of
metastasis in the SLN, such as subcapsular, parenchymal, multifocal, and extensive, would
be a reliable indicator of non-SLN status[44].
The choice of the extent of CLND is ultimately decided by the individual surgeon. Few spe‐
cific recommendations are available in the published guidelines, with the common descrip‐
tion being ‘‘a thorough dissection’’ and reports of low levels of evidence supporting the
appropriate surgical extent of CLND of the cervical, axillary, and inguinal regions[45-47].
5. Neck dissection
5.1. Extent of dissection and regional recurrence rate
The purpose of neck dissection is to control regional disease; it has little impact on overall sur‐
vival. However, the extent of neck dissection is still controversial and various extents of neck
dissection have been advocated by several authors. Radical neck dissection (RND) including
removal of level I-V (Fig. 5A) and nonlymphatic tissue such as the sternocleidomastoid muscle,
the internal jugular vein, and the spinal accessary nerve has been the gold standard for neck
dissection for melanoma[48]. Despite extensive areas of dissection, O’Brien et al. reported that
regional control with RND was unsatisfactory, with regional recurrence of 28% in patients with
all nodal disease and of 34% in patients with clinical nodal disease[48].
Generally, RND is associated with significant morbidity. Therefore, some authors have con‐
sidered modified RND (MRND) or functional neck dissection including preservation of any
or all of the sternocleidomastoid muscle, the internal jugular vein, and the spinal accessory
nerve[49, 50]. In studies of patients with clinical nodal disease, several authors demonstrat‐
ed that regional recurrence rates were 14-32% after RND, 0% after MRND, and 23% to 29%
after selective neck dissection (SND), which is not statistically significant among the
groups[51-53]. Byers also reported a 16% recurrence rate after MRND[54]. From these stud‐
ies, MRND has been advocated even in the setting of clinical nodal disease.
In addition, as an even more selective approach, the lymphatic drainage patterns of head
and neck melanoma have been described by O’Brien et al. based on a consecutive series of
over 270 neck dissections and parotidectomies (Fig. 5B)[52]. As described above, although
several authors reported relatively high regional recurrence rates of 23% to 29% after SND,
these studies include clinical N2-N3 (multiple involved nodes) disease, which will have a
higher risk of recurrence than N1 disease[51, 52]. In a study of 37 consecutive patients with
clinically N1 neck disease reported by White et al., 6 patients underwent RND, 24, MRND,
and 7, SND. None of the 3 groups had any cases of local recurrence during a mean follow-
up of 46 months[55], indicating that SND may be an alternative to RND or MRND for the
clinically N1 neck in melanoma[55].
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Furthermore, the appropriate extent of dissection is also unclear in patients with positive SLNs.
Pu et al. reported 23 consecutive patients with positive SLNs who underwent MRND or super‐
ficial parotidectomy. Of those patients, 21 (91.3%) had no additional positive non-SLNs and
only 2 (8.7 %) had 1 additional positive non-SLN[56]. No patient developed a regional local re‐
currence during a mean follow-up period of 23.7 months. The low prevalence of additional
positive non-SLNs in MRND specimens suggests that when microscopic SLN metastasis ex‐
ists, nodal disease is confined to the SLN alone in most patients [56] and SND may be selected.
As for parotid gland nodes, patients with clinically palpable parotid nodes have a 28% to
58% risk of microscopic metastasis in the cervical nodes[57-59]. Although neck dissection
should be included when clinical parotid disease is present, the need to treat the parotid no‐
des when clinical nodal disease of the neck is present is controversial. In such cases, many
surgeons selectively perform superficial parotidectomy combined with a neck dissection
based on O’Brien’s lymphatic map (Fig. 5B) or the protocol of the individual institute[60].
However, the lymphatic drainage in the head and neck is generally complex and 8% to 43%
of patients have unexpected drainage patterns in the occipital, postauricular, and contrala‐
teral nodes (Fig. 5A).[26, 61-64] Therefore, SND should be tailored to the individual patient
according to the location of the SLN and second-tier nodes.
Figure 5. A)Lymphatic anatomy of the head and neck showing the 5 major lymph node levels and superficial nodes
(B) Predicted lymphatic drainage and extent of neck dissection recommended by O’Brien et al.
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5.2. Complication rate and technical variables
Significant complications associated with radical neck dissection may include injury to the
facial and spinal accessory nerves, chylous fistula, and skin flap necrosis[65]. Although it is
generally accepted that the rate of morbidity is reduced by MRND and further reduced by
SND, detailed complication rates in the treatment of melanoma have not been reported. Ac‐
cording to the literature, neck dissection and parotidectomy is usually safe when appropri‐
ately planned preoperatively and when performed by well-experienced surgeons.
Technical variables mainly include skin incisions. Commonly used incisions are single Y, T,
or double Y-type incisions, which provide optimal exposure of the entire neck. However,
the edge of the flap sometimes has a poor blood supply and breakdown can result in the
exposure of the major vessels. The three-point suture line gives a high incidence of postoper‐
ative scar contracture[66, 67]. The Mcfee incision was designed to eliminate the three-point
exposure line, giving a good cosmetic result. However, the exposure is difficult, particularly
in a short fat neck, and excessive traction of the skin flaps can result in damaging of the skin
edges[67]. Large, single incisions such as the curtain flap, apron flap, U-flap, and Hockey
stick incision offer a good blood supply and most of the scar lies within the relaxed skin ten‐
sion lines of the neck[68]. Each incision should be selected appropriately according to the
extent of the neck dissection.
6. Axillary lymph node dissection
6.1. Extent of dissection and regional recurrence
Axillary LND for patients with melanoma is performed for local control and staging[69]; the
therapeutic value is still unclear. The axillary nodes are divided into level I, II, and III nodes.
Level I nodes are lateral to the lateral edge of the pectoralis minor muscle. Level II nodes are
between the medial and lateral edges of the pectoralis minor muscle. Level III nodes are me‐
dial to the medial edge of the pectorarlis minor muscle, in the apex of the axilla. The gener‐
ally recommended extent of dissection is from level I to III nodes because of the various
drainage patterns in the second-tier nodes as well as the potentially increased risk of recur‐
rence with a lesser dissection[70, 71]. Several authors recommended a more extensive dissec‐
tion including the supraaxillary fat pad because approximately 14% of patients will have
metastatic nodes in this area[69, 72]. In contrast, several authors have questioned whether a
level III dissection is necessary in all melanoma patients with a positive SLN and advocated
that level III dissection should be included only when suspicious nodes are present in this
level [73-75]. Namm et al. also advocated that level I and II dissection should be performed
for positive-SLN patients because of the low regional recurrence rate and low postoperative
morbidity and concluded that level III dissection is not necessary for regional control in pa‐
tients with microscopic metastasis[76].
As for the regional recurrence rate, unfortunately, most studies grouped together all of the
dissected levels. Several authors reported a 10% to 19% regional recurrence rate during
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about a 30-month median follow-up[77-79]; however, in all 3 of those studies, the extent of
dissection was not documented. Veenstra et al. reported a 4% regional recurrence rate and
documented which levels were included when axillary LND was performed; however, they
did not tease out the axillary recurrence rate specifically[80]. In the case of level I and II dis‐
section for patients with a positive SLN, a low recurrence rate of 4% during a median fol‐
low-up of approximately 39-month was reported[76].
6.2. Complication rate and technical variables
Wrightson et al. reported a 19.9% complication rate among 262 patients undergoing axillary
LND, most of which was thought to be level I-III dissection, for a positive SLN[81]. Several
authors reported a complication rate of 14% to 21% for wound infection and of 19% to 36%
for lymphocele when performing level I–III dissections[82, 83]. In contrast, Numm et al. re‐
ported that postoperative complications occurred in 11% of patients, with infectious compli‐
cations in 8% when performing level I and II dissection. However, comparative studies of
level I-II dissection with and level I-III dissection have not been published. Although the
definition of lymphedema varies among studies, a long-term lymphedema rate was report‐
ed to be 1% to 12%[72, 75, 81].
Evidence of an optimal surgical technique for axillary LND has not been shown. As tech‐
nical modifications, 2 incisions are mainly used. One is a transverse incision from the lat‐
eral edge of the pectoralis major muscle to the border of the latissimus dorsi muscle, and
the other is an extended incision following the contour of the pectoralis major into the ax‐
illary  apex  and  then  down  the  medial  arm[72,  84].  However,  these  incision  variables
would not affect the complication rate. Lawton et al. advocated preservation of the pector‐
alis major, the interpectoral, and the latissimus dorsi fascia during axillary LND to try to
reduce  lymphedema[84].  Over  110  elective  and  therapeutic  fascia-preserving  axillary
LNDs  developed  a  5%  incidence  of  long-term  lymphedema,  which  is  the  same  as  or
slightly  lower  than  the  incidence  rates  reported  by  the  studies  [72,  75,  81]  described
above. Optimal surgical exposure for level III dissection sometimes requires transection of
the pectoralis minor muscle, and several authors suggested routine en bloc dissection of
the pectoralis minor for TLND[16, 72, 75]. The long thoracic and thoracodorsal nerves are
routinely  preserved,  although  the  intercostobrachial  nerves  are  often  sacrificed  in
TLND[73, 75]. As a result, no modifications clearly improve the complication rate, and on‐
ly the extent of dissection impacts the complication rate.
7. Ilioinguinnal lymph node dissection
7.1. Extent of dissection and regional recurrence rate
The dissection areas subject  to most  controversy are inguinal  LND alone or  ilioinguinal
LND  (inguinal  LND  +  iliac/obturator  (pelvic)  LND).  When  iliac  or  obturator  node  in‐
volvement  is  suspected  clinically  or  radiologically,  additional  pelvic  LND  is  generally
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recommended[74, 85-87]. For patients with clinically palpable nodal disease in the ingui‐
nal  region  alone,  additional  pelvic  LND  has  not  been  widely  accepted  because  of  the
lack of overall survival advantage[88, 89]. However, some authors advocated ilioinguinal
LND because the rate of pelvic lymph node involvement in patients with palpable ingui‐
nal disease is 27% to 52%[87-92]. In a study of predictive factors for pelvic nodal status,
Strobbe et al.  reported that the Cloquet node has a limited sensitivity of 65% to predict
involvement  of  the  pelvic  nodes  and  that  the  negative  predictive  value  is  78%.  In  pa‐
tients with clinical inguinal nodal disease, a tumor-positive Cloquet node had a 69% risk
(positive  predictive  value)  of  additional  positive  nodes[91].  They  also  showed  that  the
number of positive nodes in the inguinal region is not a reliable predictive factor for the
pelvic nodal status, with a sensitivity of 41% and a negative predictive value of 78%[91].
Furthermore, the extent of dissection is more controversial in positive inguinal SLN patients.
Van der Ploeg et al. reported that there is no lymphatic drainage to the inferior lateral zone,
which is just lateral to the femoral artery and inferior to the level of saphenofemoral junction
in the inguinal area, in patients with a positive SLN and advocated that this area need not be
included in LND for such patients[93]. Pelvic nodes also seem unlikely to be involved when
an inguinal SLN shows only microscopic metastasis[94, 95]. Several authors reported that
9% to 17 % of patients with a positive inguinal SLN also have positive pelvic nodes when
ilioinguinal LND is performed[96-98]. In addition, a study evaluating lymphatic flow using
lymphoscintigraphy and/or SPECT/CT demonstrated that over 50% of patients with a posi‐
tive SLN showed second-tier nodal drainage to the pelvic nodes[93]. This study suggests
that a selective pelvic LND based on the location of the second-tier nodes may be appropri‐
ate in positive SLN patients[93, 99].
As for the regional recurrence rate, published recurrence rates after inguinal or ilioinguinal
LND for patients with clinical nodal disease is 0% to 33.6% (inguinal LND: 11.7%-13%;
ilioinguinal LND: 0%-17.9%)[74, 85-89]. Sterne et al. reported that patients with palpable no‐
dal disease who underwent inguinal LND alone had a regional recurrence rate of 12.5% (2 of
16 patients), whereas for those who underwent ilioinguinal LND, it was 0% (0 of 25 patients)
[85]. Pearlman et al. reported a modification of inguinal LND that does not violate the femo‐
ral sheath. However, a 16% rate of regional recurrence was reported[100].
7.2. Complication rate and technical variables
In the field of urology, classical inguinal LND has traditionally been associated with an 80%
to 100% risk of surgical morbidity[101]. In the treatment of melanoma, several authors re‐
ported that 20% to 77% of patients who underwent inguinal LND had postoperative mor‐
bidity such as skin necrosis and wound dehiscence (7%-55%), wound infection (5%-15%),
lymphocele/seroma (2%-46%), and lymphedema (5%-64%).[102] Although concerns have
been raised about the potential for increased morbidity in patients undergoing an additional
pelvic LND[87, 103], the addition of pelvic LND to inguinal LND did not significantly in‐
crease the risk for postoperative wound complication[87, 101, 104, 105]. However, lymphe‐
dema was more common after inguinal LND alone in some studies, although 1 study
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specifically evaluating the incidence of lymphedema found no difference between the 2 pro‐
cedures[87, 106, 107]. The lack of consensus about the complications of additional pelvic
LND may suggest that when clinically indicated, concern about increased morbidity should
not be a reason to avoid ilioinguinal LND, although patients may suffer from the operating
time and cost.
The commonly described technical variables of ilioinguinal LND include different type of
skin incision, thick skin flap, preservation of the large saphenous vein, transposition of the
sartorius muscle over the femoral vessels, continuity dissection with division of the inguinal
ligament, and trimming of the skin edges at the time of closure[108].
Several skin incisions are used: a Lazy-S incision from just medial to the anterior superi‐
or iliac spine to the inferior margin of the femoral triangle, paired oblique incisions (Fig.
6A), or an oblique/transverse incision above the inguinal crease with a longitudinal inci‐
sion below and a skin bridge between[73,  84,  100].  Lazy-S incision provides optimal ex‐
posure  and  less  subcutaneous  lymphatic  disruption[108].  In  contrast,  paired  oblique
incisions or an oblique/transverse incision can avoid an incision in the inguinal crease to
reduce skin necrosis and wound dehiscence[84]. Recently, however, Spillane et al. report‐
ed  minimal-access  3-  to  6-cm-long  paired  incisions  above  and  below  the  inguinal  liga‐
ment,  which  showed  no  significant  difference  in  wound  and  lymphedema
complications[109].  A thick  skin  flap elevated at  the  level  of  the  Scarpa fascia  may im‐
prove skin necrosis and wound dehiscence rates; however, a 26% to 34% rate of skin ne‐
crosis  and  wound  infection  was  reported[84,  100].  The  preservation  of  the  saphenous
vein  and the  sartorius  transposition  flap  for  vessel  coverage  were  designed to  improve
lymphedema rates,  with  no  incidence  of  lymphedema[100].  When performing  ilioingui‐
nal LND, technical variables include a continuity dissection by dividing the inguinal liga‐
ment or an abdominal wall incision above and parallel to the inguinal ligament (Fig. 6B)
to expose the retroperitoneal space[73, 84, 86]. Although advantages of inguinal ligament
division include optimal exposure and possible continuity dissection, the main disadvant‐
age is possible long-term abdominal wall weakness that may lead to abdominal incision‐
al hernia. As another modification, Lawton et al. advocated fascia-preserving ilioinguinal
LND, which is similar to the modified axillary dissection described above in the section
on axillary LND, and the long-term lymphedema rate was 14%. Video-assisted endoscop‐
ic  inguinal  LND is  currently  investigated  as  a  minimally  invasive  and less  morbid  ap‐
proach but is not widely used[110, 111].
Despite such modifications, a comparative study reported by Sabel et al. demonstrated no
significant difference in wound and lymphedema complications between modified inguinal
LND (incision avoiding the inguinal crease, saphenous vein preservation, or sartorius trans‐
position) and conventional inguinal LND[107]. However, although insignificant, saphenous
vein preservation decreased the lymphedema rate from 30% to 13% and the wound compli‐
cation rate from 20% to 7%. An incision avoiding the inguinal crease also decreased the
wound complication rate from 21% to 9%, which is also statistically insignificant. Thus,
these modifications seem to offer promise in decreasing morbidity.
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Figure 6. Ilioinguinal LND using paired incisions. (A) Incision lines. The incision below the inguinal crease is fusiform
to include the skin overlying the metastatic node. (B) Operating field after dissection. The abdominal wall was incised
parallel to the inguinal ligament, which was preserved under the bipedicle flap.
As another procedure in an attempt to decrease lymphocele, Nakamura et al. reported a
simple method using intraoperative injection of isosulfan blue during inguinal LND without
modifications to identify leakage from an injured lymphatic vessels for the prevention of
lymphocele (Fig. 7)[112]. There was no incidence of lymphocele in the isosulfan blue injec‐
tion group and the lymphatic drainage output from the inguinal region was clearly less,
leading to early removal of the suction catheter.
Despite many technical variables, it is difficult to evaluate each technique because of the dif‐
ferent study designs, variable definitions of complications, and different patient popula‐
tions. Multicenter, randomized prospective trials with a standardized definition of
complications are required in the future.
Figure 7. Intraoperative injection of blue dye during inguinal LND for detection of injured lymphatic vessels. (A) Intra‐
cutaneous injection of isosulfan blue around the right inguinal region just after inguinal LND. (B) Blue-staining lym‐
phatic leak (arrow) in the surgical field, which was ligated.
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8. Adjuvant radiation therapy
Regional recurrence occurs in 20% to 50% of patients after TLND. High-risk factors associat‐
ed with regional recurrence include a cervical lymph node basin, large lymph nodes, multi‐
ple positive lymph nodes, and extracapsular extension[113]. Patients with such risk factors
are appropriate candidates for adjuvant radiation therapy, and several nonrandomized
studies have demonstrated that adjuvant radiation therapy after CLND for patients with re‐
gional nodal disease can reduce the risk of regional recurrence to between 5% and 20%
[114-118]. In a prospective phase II study by the Trans Tasman Radiation Oncology Group
(TROG Study 96.06) of adjuvant radiation therapy after CLND for patients with regional no‐
dal disease, the regional control rate was 91%[118].
Although adjuvant radiation therapy can be effective in achieving regional control after
TLND, it increases chronic lymphedema, particularly in the inguinal region, which is the
major morbidity associated with TLND[119].
9. Conclusions
The surgical approach to regional lymph node metastasis of cutaneous melanoma is chal‐
lenging. SLNB allows accurate staging of nodal status and prediction of prognosis. A posi‐
tive SLN should be treated with CLND for regional control. However, the impact on SLNB
on overall survival remains unclear, and the appropriate surgical extent of CLND in the cer‐
vical, axillary, and inguinal regions is also debated. More research is required to provide
evidence-based guidelines for surgeons about the extent of LND and to investigate the fac‐
tors that may lead to a more patient-tailored approach.
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